Search research articles
Contact Us
Filters
Showing results (151-160 of 157) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 157 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2022
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
John F R Robertson, Robert E Coleman, Kwok-Leung Cheung, et al.
JAMA Network Open
|
May 13, 2025
Integrated Collaborative Care for Youths With Mental Health and Substance Use Challenges: A Randomized Clinical Trial
Jo Henderson, Peter Szatmari, Kristin Cleverley, et al.
The Lancet. HIV
|
January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
Aditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
Depression and Anxiety
|
May 10, 2013
Cognitive behavioral therapy age effects in child and adolescent anxiety: an individual patient data metaanalysis
Kathryn Bennett, Katharina Manassis, Stephen D Walter, et al.
Ebiomedicine
|
November 14, 2021
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
Brian M Maas, Jos Lommerse, Nele Plock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
The Lancet. HIV
|
March 6, 2025
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
Carolyn Bolton Moore, Kristin Baltrusaitis, Brookie M Best, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 157) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 157 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2022
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
John F R Robertson, Robert E Coleman, Kwok-Leung Cheung, et al.
JAMA Network Open
|
May 13, 2025
Integrated Collaborative Care for Youths With Mental Health and Substance Use Challenges: A Randomized Clinical Trial
Jo Henderson, Peter Szatmari, Kristin Cleverley, et al.
The Lancet. HIV
|
January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
Aditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
Depression and Anxiety
|
May 10, 2013
Cognitive behavioral therapy age effects in child and adolescent anxiety: an individual patient data metaanalysis
Kathryn Bennett, Katharina Manassis, Stephen D Walter, et al.
Ebiomedicine
|
November 14, 2021
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
Brian M Maas, Jos Lommerse, Nele Plock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
The Lancet. HIV
|
March 6, 2025
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
Carolyn Bolton Moore, Kristin Baltrusaitis, Brookie M Best, et al.
Page
of 16